Cancer News
OncoLink Cancer News - HealthDay


Prognostic Factors Identified in Mucoepidermoid Carcinoma

Friday, August 10, 2012 (Last Updated: 08/13/2012)

FRIDAY, Aug. 10 (HealthDay News) -- Diagnosis of low- or intermediate-grade tumors is associated with significantly better overall survival and disease-free survival in patients with mucoepidermoid carcinoma (MEC) of the salivary glands, while advanced disease stage and perineural invasion are the most significant indicators of poor prognosis, according to a study published in the Aug. 15 issue of Cancer.

Catherine H. McHugh, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues retrospectively reviewed clinical data from 125 patients with salivary gland MEC from 1990 to 2007.

The researchers found that, for all patients, the five-year overall survival was 79.3 percent and the disease-free survival was 76.5 percent. Low- and intermediate-grade disease correlated with significantly better overall and disease-free survival than high-grade disease, with no difference noted in survival rates between low- and intermediate-grade disease. Indicators of poor prognosis included pathologic results of positive lymph nodes, extracapsular lymph node spread, and perineural invasion. Advanced disease stage and perineural invasion were found to be the most significant prognostic factors on multivariate analysis.

"High histological grade, advanced stage, perineural invasion, positive surgical margins, and submandibular location all portend for unfavorable outcomes among patients with MEC," the authors write. "These factors should therefore be taken into consideration when establishing the aggressiveness of a treatment strategy."

Abstract
Full Text (subscription or payment may be required)

Specialties Hematology & Oncology
Pathology
Otolaryngology

Copyright © 2012 HealthDay. All rights reserved.


I Wish You Knew

Nutrition During Cancer Treatment

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More